Catalog No.
EHD13201
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Ala38-Met533
Predicted molecular weight
83.7 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P15848
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Arylsulfatase B, ASB, 3.1.6.12, N-acetylgalactosamine-4-sulfatase, G4S, ARSB
Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study., PMID:40510111
Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15 years follow-up., PMID:40381595
Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials., PMID:40317013
Histopathological and Clinical-Genetic Analysis of Corneal Specimens in Maroteaux-Lamy Syndrome., PMID:40079783
Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database., PMID:39161895
Novel chorioretinal findings in two siblings with mucopolysaccharidosis type VI., PMID:35658818
Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report., PMID:35078524
Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan., PMID:34987750
Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series., PMID:34666789
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI., PMID:34533215
Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy., PMID:33775523
Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study., PMID:33678523
Home treatment of type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome) an alternative at this time of COVID-19 pandemic: A case in Peru., PMID:33363956
Enzyme Replacement Therapy may Affect Blood Immunosuppressant Monitoring., PMID:32379593
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations., PMID:32340185
[Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI]., PMID:31582674
Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program., PMID:31324526
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance., PMID:31142378
Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program., PMID:30834539
Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review., PMID:30740728
What does mainstream media say about enzyme replacement therapies?, PMID:30455582
Family study of a novel mutation of mucopolysaccharidosis type VI with a severe phenotype and good response to enzymatic replacement therapy: Case report., PMID:30335002
Lysosomal storage diseases., PMID:29152458
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up., PMID:28983456
The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)., PMID:28457718
Is premedication a necessity before galsulfase replacement therapy?, PMID:27346567
A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI., PMID:27164636
Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series., PMID:27134829
Rapid Desensitization for Immediate Hypersensitivity to Galsulfase Therapy in Patients with MPS VI., PMID:26951141
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI., PMID:26943923
Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome., PMID:26920906
Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations., PMID:26776148
[Management of mucopolysaccharidosis type VI in adults]., PMID:26502669
Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children., PMID:28649537
Enzymes approved for human therapy: indications, mechanisms and adverse effects., PMID:25648140
Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)., PMID:25518809
[Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy]., PMID:24862809
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study., PMID:24764221
Early initiation of enzyme replacement therapy for the mucopolysaccharidoses., PMID:24388732
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI., PMID:24108527
Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases., PMID:24060239
Oral manifestations of 17 patients affected with mucopolysaccharidosis type VI., PMID:23974652
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase., PMID:23557332
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI., PMID:23535281
Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme]., PMID:23244660
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy., PMID:22669363
Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation., PMID:22495825
Therapy for the mucopolysaccharidoses., PMID:22210671
For research use only. Not for human or drug use.
